Medtronic's 49-Year Dividend Streak Faces a New Challenge: Is Growth Finally the Real Story?

Impact · against what's priced in

Medtronic's strong cardiac ablation growth and the Diabetes spinoff are already factored into the current valuation, leaving only the upcoming investor day as a new catalyst. Boston Scientific's price has already fully absorbed the organic growth outlook cuts, while Abbott's mentions are non-material.

BSX+0.00

Already priced in

The price assumes

The lowered full-year organic growth guidance of 6.5% to 8.0% and the reduced earnings guidance of $3.34 to $3.41 per share